Akeso's Upcoming 2024 Financial Results Conference Call
Akeso Inc. (9926.HK) is gearing up to hold an important conference call that will cover its final financial results for the year 2024. This call is scheduled for March 31, and it promises to provide valuable insights into the company's performance over the year and a glimpse into what the future may hold.
Conference Call Timing and Participation
The call will occur at various times across key global locations. For those in Hong Kong and Singapore, it will run from 20:00 to 21:00. In London, the session will start at 13:00 and for those in New York, it will take place from 08:00 to 09:00. Investors and other stakeholders are encouraged to participate, as the management team will address burning questions and share crucial information.
Key Management Presenting
Notable figures from Akeso's executive team will present during this call. Key attendees will include Dr. Michelle Xia, the Chairwoman, President & CEO, along with Dr. Baiyong Li, the Chief Scientific Officer, and Dr. Bing C. Wang, the Chief Financial Officer. They will work together to give an overview of the company's financial landscape, discussing not only outcomes but also expectations for 2025.
Innovative Pipeline Insights
During the call, the management team will dive deep into Akeso's innovative pipeline. This discussion will focus on recent developments and the progress of significant therapies that the company has in the works. They will highlight advancements in bispecific antibodies like cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF). Additionally, updates regarding the CD47 monoclonal antibody, antibody-drug conjugates (ADCs), and bispecific ADCs are on the agenda.
About Akeso
Founded in 2012, Akeso has quickly risen to become a frontrunner in the biopharmaceutical industry. The company is dedicated to the development, manufacturing, and commercialization of innovative biological medicines, striving to deliver groundbreaking solutions in healthcare. Their research and development ecosystem, particularly the ACE Platform, comprises an end-to-end drug development approach that optimally supports the advancement of over 50 innovative therapeutic assets across various significant diseases, including cancer, autoimmune diseases, and metabolic disorders.
As of now, Akeso has 23 candidates in clinical trials, including a number of bispecific/multispecific antibodies and ADCs. Furthermore, the company boasts six new drugs that are commercially available, alongside five additional drugs currently undergoing regulatory review for approval across seven indications. Akeso's mission remains to integrate superior global resources to create first-in-class and best-in-class drugs, ensuring availability and affordability for patients worldwide.
Frequently Asked Questions
1. What date is the Akeso conference call scheduled for?
The conference call is scheduled for March 31, 2025.
2. Who will be presenting during the call?
The call will feature Dr. Michelle Xia, Dr. Baiyong Li, and Dr. Bing C. Wang from Akeso's management team.
3. What topics will be discussed during the call?
The call will cover the financial results of 2024, insights into the innovative pipeline, and future strategic directions of the company.
4. How can investors participate in the call?
Investors can participate by pre-registering for the call. They may also contact their Morgan Stanley sales representative for further details.
5. What is Akeso's focus in the biopharmaceutical industry?
Akeso focuses on the research and development of innovative biological medicines, primarily in the fields of cancer and other significant diseases.
